EPRXEupraxia Pharmaceuticals Inc.
What is the market doing?
In an uptrend. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
In an uptrend, above its rising 50- and 200-day averages. Price is +3% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How EPRX is trading
Eupraxia Pharmaceuticals Inc. is +26% over the past year while the S&P 500 is +18%: 7.7 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +3.0%
vs 200-day average · close to trend
- RSI (14)
- 39
RSI (14) · neutral
- Below its 52-week high
- 17%
Below its 52-week high
Details›
- Last close2026-10-08
- $7.58
- 1 monthS&P 500 +1.6%
- −6.0%
- 1 yearS&P 500 +18%
- +26%
- vs 50-day average$7.45
- +1.7%
- 52-week high
- $9.12
- 52-week low
- $5.33
- Annualised volatility
- 67%
| Year | Return |
|---|---|
| 2026 (year to date) | +0.40% |
| 2025 | +138% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 1 of 2 | +0.51% |
| Feb | 2 | 1 of 2 | +19% |
| Mar | 2 | 0 of 2 | −15% |
| Apr | 2 | 2 of 2 | +16% |
| May | 3 | 0 of 3 | −5.2% |
| Jun | 3 | 1 of 3 | +12% |
| Jul | 3 | 1 of 3 | +0.24% |
| Aug | 3 | 1 of 3 | −3.4% |
| Sep | 3 | 3 of 3 | +18% |
| Oct | 3 | 0 of 3 | −9.3% |
| Nov | 2 | 2 of 2 | +23% |
| Dec | 2 | 1 of 2 | +8.1% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry